-+ 0.00%
-+ 0.00%
-+ 0.00%

Bristol-Myers Squibb Lowers FY2026 Adj EPS Guidance from $6.75-$7.00 to $6.35-$6.55 vs $6.54 Est; Raises FY2026 Sales Guidance from $49.000B-$50.000B to $49.750B-$50.250B vs $49.886B Est

Benzinga·10/29/2026 11:00:48
Listen to the news
Bristol-Myers Squibb (NYSE:BMY) lowers FY2026 Adj EPS guidance from $6.75-$7.00 to $6.35-$6.55 vs $6.54 analyst estimate. Raises FY2026 sales outlook from $49.000 billion-$50.000 billion to $49.750 billion-$50.250 billion vs $49.886 billion estimate.